Evidence map›Paper›PMID 40159652›Full record

ArticleJournal of cellular and molecular medicine2025

Unravelling Cancer Immunity: Coagulation.Sig and BIRC2 as Predictive Immunotherapeutic Architects.

Ziang Yao, Jun Fan, Yucheng Bai, Jiakai He, Xiang Zhang, Renquan Zhang, Lei Xue

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ziang YaoDepartment of Traditional Chinese Medicine, Peking University People's Hospital, Beijing, China.
Jun FanDepartment of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.ORCID 0009-0009-0713-5411
Yucheng BaiDepartment of Thoracic Surgery, First Affiliated Hospital, Anhui Medical University, Hefei, China.
Jiakai HeDepartment of Traditional Chinese Medicine, Peking University People's Hospital, Beijing, China.
Xiang ZhangDepartment of Respiratory and Critical Care Medicine, The Affiliated Huai'an Hospital of Xuzhou Medical University, the Second People's Hospital of Huai'an, Huai'an, Jiangsu, China.
Renquan ZhangDepartment of Thoracic Surgery, First Affiliated Hospital, Anhui Medical University, Hefei, China.
Lei XueDepartment of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.ORCID 0000-0003-2106-6220

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) represent a groundbreaking advancement in cancer therapy, substantially improving patient survival rates. Our comprehensive research reveals a significant positive correlation between coagulation scores and immune-related gene expression across 30 diverse cancer types. Notably, tumours exhibiting high coagulation scores demonstrated enhanced infiltration of cytotoxic immune cells, including CD8

Indexed as

Blood CoagulationImmunotherapyInhibitor of Apoptosis ProteinsNeoplasmsUbiquitin-Protein LigasesBiomarkers, TumorCD8-Positive T-LymphocytesGene Expression Regulation, NeoplasticHumansImmune Checkpoint InhibitorsTumor MicroenvironmentBiomarkers, TumorBIRC2 protein, humanImmune Checkpoint InhibitorsInhibitor of Apoptosis ProteinsUbiquitin-Protein LigasesBIRC2coagulationimmune checkpoint inhibitorimmunotherapypan‐cancer

Identifiers

PMID40159652
PMCPMC11955421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.